Bergen, 3 June 2025 - Reference is made to previous stock exchange announcements
from BerGenBio ASA ("BerGenBio" or the "Company") dated 25 February 2025 and 17
March 2025 regarding the Company's ongoing strategic review process.

Strategic review process is ongoing

With reference to the announcement 17 March 2025, engaging DNB Carnegie as
financial advisor for the strategic review process, the process remains ongoing.
As previously communicated, the Board of Directors will, as part of this
process, consider a range of options for the Company, including, among other
things, a potential sale, merger, or other strategic transaction. There can be
no assurance that this review will result in any transaction. The Company will
announce further updates when appropriate and expects to conclude the process by
the end of July.

Closedown of remaining bemcentinib activities

The Board of Directors has decided to discontinue all remaining development
activities for bemcentinib as there are limited financial justification to
pursue further activities.

Estimated free cash after closure of activities

The Company has implemented significant cost-containment and cash conservation
measures. Free cash after closure of all activities and settlement of any
potential liabilities is estimated to be in the range of NOK 40 - 45 million.

Contacts

Olav Hellebø, CEO BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Jan Lilleby, Investor Relations / Media Relations
jl@lillebyfrisch.no

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies, and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.